Q3 Revenue Falls 11% as Recall Wipes Out U.S. Sales; Cash Down to $19M
NSPR has more than doubled off its 52-week low of $0.425 on elevated volume (2.4× avg).
Summary
Q3 revenue came in at $2.24M, down 11.1% from $2.52M a year ago, because U.S. sales collapsed to $32K from $497K after the May 2026 voluntary recall of the CGuard Prime CAS delivery system, though the revenue figure beat analyst estimates. Gross margin cratered to 10.7% from 34.2%, and the net loss was $9.76M, or $0.12 a share, versus $12.71M a year earlier — the smaller loss came from cutting operating expenses 26.7% to $10.19M, including $1.07M of restructuring tied to the workforce reduction. Cash and marketable securities fell to $19.25M from $54.21M at year-end, a burn rate that keeps the going-concern question front and center. The offset is the FDA approval of CGuard Prime for TCAR announced earlier today, which the company says adds over 35,000 procedures a year to its addressable market and should roughly double the U.S. opportunity, with U.S. sales starting in Q4 2026. Watch the 4:30 pm ET call today for launch timing and how they plan to fund the rollout, and the PMA supplement for the enhanced CAS delivery system targeted for December 2026.
At the time of this announcement, NSPR was trading at $0.91 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $36M. The 52-week trading range was $0.43 to $2.22. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.